Nebivolol for the Prevention of Left Ventricular Systolic Dysfunction in Patients With Duchenne Muscular Dystrophy

Inclusion Criteria: * Duchenne muscular dystrophy genetically proven * Age between 10 and 15 years * Left ventricular ejection fraction assessed by radionuclide angiography or echocardiography ≥50% and measured within 3 months * Systolic blood pressure ≥80 mmHg * Diastolic blood pressure ≥70 mmHg Exclusion Criteria: * Heart rate \<50 bpm * 2nd or 3rd degree atrioventricular blocks, sinus node dysfunction * Asthma or bronchospasm * Severe peripheral circulatory disease * Hypersensitivity to nebivolol or excipients * Metabolic acidosis * Blood urea \>7 mmol/l * Liver transaminases enzymes \>6 fold the upper limit of normal * Formal indication for beta-blockade treatment * Cardiac treatments except angiotensin-converting enzyme inhibitors * Participation to another clinical trial within 3 months